Why Westlake stock is jumping today after its ACI deal filing
8 January 2026
1 min read

Why Westlake stock is jumping today after its ACI deal filing

NEW YORK, Jan 8, 2026, 13:30 EST — Regular session

Westlake Corp (WLK) shares jumped 7.4% in early afternoon trading on Thursday, extending a sharp intraday rebound after the chemical maker disclosed it had completed an acquisition in its compounds business. The stock was up $5.51 at $79.98, after ending Wednesday at $74.47.

The purchase matters now because Westlake is leaning harder into specialty compounds — plastics tailored for specific uses — as investors look for steadier earnings in a sector that can swing with construction demand and commodity chemical pricing. Compounding is the work of blending a base polymer with additives to make a material with specific properties, such as flexibility or heat resistance.

The move came alongside broad gains in U.S. chemicals. Dow was up 4.1%, LyondellBasell rose 5.7% and Huntsman gained 5.4%, outpacing the wider market’s more uneven tone.

In an SEC filing dated Jan. 6, Westlake said it completed its previously announced acquisition of the global compounding solutions businesses of the ACI/Perplastic Group. Chief executive Jean-Marc Gilson said the deal “represents a strong strategic alignment” for Westlake’s Housing & Infrastructure Products business, while Maribel Wilson, vice president of Westlake Global Compounds, said ACI had built a reputation for “innovative, high-value solutions.” 1

Westlake said ACI is headquartered in Portugal and makes specialty materials that mainly serve wire and cable markets, and that the acquisition expands Westlake Global Compounds’ manufacturing footprint into Portugal, Romania and Tunisia, adding to operations in Mexico. The company did not disclose financial terms. 2

Westlake is a Houston-based manufacturer and supplier spanning commodity chemicals and building products, with businesses ranging from chlor-alkali and chlorovinyls to pipes, fittings and building materials. 3

The company has been trying to steady results after a tough 2025 for parts of its commodity chemicals portfolio. In its most recent quarterly report, Westlake posted a net loss and said weaker industrial and manufacturing conditions had weighed on pricing and margins in its Performance and Essential Materials segment, particularly chlorovinyls, which includes PVC resin used in pipes and other construction products. 4

But the bounce in the shares does not erase the core risk: Westlake still lives with a chemical cycle that can turn fast, and the ACI deal adds integration work across multiple countries at a time when investors are watching costs closely. If pricing for PVC and other commodity products slips again, or if end-markets tied to housing cool further, the stock’s rally can fade just as quickly.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Floor & Decor stock jumps 7% today — here’s what traders are watching next
Previous Story

Floor & Decor stock jumps 7% today — here’s what traders are watching next

Regencell Bioscience (RGC) stock slides about 18% after five volatility halts on Nasdaq
Next Story

Regencell Bioscience (RGC) stock slides about 18% after five volatility halts on Nasdaq

Go toTop